hers compounded semaglutide safety Hims & plans to launch $49 copy of Wegovy pill Novo Nordisk calls out dangers

Biosimilar developers seeking to launch with labels covering those indications had to contend with these indication-specific patents

Sermorelin is not a weight loss medication

The LEADER trial with liraglutide and the REWIND trial with dulaglutide did not show significant increases in retinopathy complications, though differences in trial design, patient populations, baseline retinopathy prevalence, and rates of glycemic improvement may explain these discrepant findings

The allowance for investigators to use all available information (for example, concomitant medication) to assess glycemic category was primarily included to account for scenarios in which glucose-lowering medications were initiated during the trial that would confound glycemic category assessment if based purely on fasting plasma glucose or HbA 1c levels (for example, if a patient developed diabetes during the study and received a glucose-lowering drug that resulted in their glucose level being below the American Diabetes Association threshold for type 2 diabetes diagnosis)